The research interests of the division cover the following areas: HIV/AIDS; transplantation infectious diseases; experimental pharmacology; fungal infections; pathogenesis of Epstein-Barr virus-mediated cell transformation, viral subversion of host growth, survival, and epigenetic pathways; pathogenesis of Kaposi’s sarcoma-associated herpesvirus (HHV-8); streptococcal and other bacterial infections, vaccine development; social medicine; tuberculosis; tropical medicine; human intestinal microbiota studies ,and clinical epidemiology. The clinical microbiology laboratory offers a full range of procedures for isolation and identification of bacterial, mycobacterial, fungal, parasitic, and viral infections; antibiotic susceptibility testing; and serology tests for infectious agents.
The Division occupies research space in the main hospital (PBB-A4), the Massachusetts College of Pharmacy Building (former Channing Laboratory) on Longwood Avenue, 900 Commonwealth Avenue and the Partners Research Facility on Lansdowne Street in Cambridge, MA. The division received $15 million in total direct research awards (not counting the ACTG Leadership Operations Center) in 2013.
The division is involved in a variety of clinical research activities related to novel therapeutics. In particular, we have ongoing studies related to the treatment of resistant bacteria pathogens, fungi, and HIV. We are active participants in the AIDS Clinical Trials Group (ACTG) and the HIV Vaccine Trials Network (HVTN).
Specific Areas of Interest:
Click each topic below for a detailed description and a list of faculty members researching in this field.